Evidence map›Paper›PMID 31511075›Full record

ArticleJournal for immunotherapy of cancer2019

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.

N Shah, J Jacob, Z Househ, E Shiner, L Baird, H Soudy

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

N ShahSt George-Sutherland Basic Physician Training Network, Kogarah, New South Wales, Australia. nasir.shah@health.nsw.gov.au.ORCID 0000-0001-8997-2161
J JacobSt George-Sutherland Basic Physician Training Network, Kogarah, New South Wales, Australia.
Z HousehDepartment of Anatomical Pathology, SEALS, St George Hospital, Kogarah, New South Wales, Australia.
E ShinerDepartment of Neurology, St George Hospital, Kogarah, New South Wales, Australia.
L BairdDepartment of Aged Care, St George Hospital, Kogarah, New South Wales, Australia.
H SoudyFaculty of Medicine, University of New South Wales, Kensington, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibition has dramatically transformed the treatment of malignant melanoma. With increasing use, their unique spectrum of immune-mediated toxicity has become apparent. CASE PRESENTATION: We describe a case of sequential immune-related adverse events (irAEs) in a patient with metastatic melanoma treated with single-agent anti-programmed cell death-1 (PD-1) therapy, pembrolizumab. Although numerous cases of irAEs have been reported, sequential multi-organ involvement, including progressive atopic dermatitis, vitiligo, autoimmune nephritis, autoimmune hepatitis, and autoimmune encephalitis after cessation of therapy, has not been previously documented.

conclusionsImmunosuppression resulted in clinical remission of each irAE, highlighting the importance of vigilance for autoimmune complications in patients treated with checkpoint inhibition, even after immunotherapy cessation.

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDermatitis, AtopicEncephalitisHepatitis, AutoimmuneHumansImmunotherapyMaleMelanomaNephritis, InterstitialPrognosisVitiligoAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabCheckpoint inhibitorsImmune-related adverse eventsMalignant melanoma

Identifiers

PMID31511075
PMCPMC6740018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.